Smart Cancer Drug May Target Tumour Cells While Sparing Healthy Cells, Study Finds

Cancer treatment has made significant progress, but one of its biggest challenges remains the damage that some treatments can cause to healthy cells. Traditional chemotherapy can attack rapidly dividing cancer cells, but it may also affect healthy cells, leading to side effects.

Now, scientists in India have developed a new experimental cancer drug designed to work differently. Called RK 251, the drug is designed to remain largely inactive in healthy tissues and become activated mainly inside cancer cells.

The research was led by Dr Asis Bala from the Institute of Advanced Study in Science and Technology, an autonomous institute under the Department of Science and Technology, along with Dr K P Bhabak from the Indian Institute of Technology Guwahati. The findings were published in the ACS Journal of Medicinal Chemistry.

What Is The New Cancer Drug RK 251?

RK 251 is described as a smart cancer drug because it is designed to recognise a chemical environment that is more common inside cancer cells.

Cancer cells often produce high levels of molecules known as reactive oxygen species, or ROS. These molecules can damage cells, but cancer cells can also use altered levels of ROS as part of their growth and survival processes.

Researchers designed RK 251 to take advantage of this difference between cancer cells and healthy cells.

Also Read: What Is Palliative Chemotherapy? How It Differs From Regular Chemotherapy

How Does RK 251 Work?

The drug enters cells in an inactive form. When it encounters high levels of reactive oxygen species inside a cancer cell, the drug is activated.

This releases an anticancer compound called NBDHEX.

NBDHEX works by blocking target proteins that many cancer cells depend on to survive and resist treatment. This means the drug is designed to deliver its active cancer-fighting compound where it is most needed, rather than exposing healthy tissues to the same level of activity.

The approach could potentially reduce some of the unwanted effects associated with treatments that also damage healthy cells.

What Did The Early Research Show?

In preclinical laboratory studies, RK 251 showed strong activity against aggressive triple negative breast cancer cells.

Triple negative breast cancer is a type of breast cancer that does not have three commonly targeted receptors. Because these cancers lack these receptors, treatment options can be more limited compared with some other forms of breast cancer.

The researchers found that RK 251 had a much smaller effect on healthy cells in their studies, suggesting that the drug's activation mechanism may provide a degree of selectivity.
However, these findings are still at an early stage.

Also Read: When Cancer Spreads to the Bone: Early Signs, Treatments and Why It Doesn't Always Mean the End

What did the zebrafish study find?

Researchers also studied the behaviour of the drug candidate using zebrafish embryos.

The study did not show obvious signs of toxicity in the embryos. The drug also produced the expected fluorescence when reactive oxygen species were present.

This fluorescence helped researchers observe the drug's response to its intended chemical trigger.

The findings provide additional evidence supporting further investigation of RK 251, but they do not establish that the drug is safe or effective in humans.

Can It Replace Chemotherapy?

The possibility of replacing or reducing traditional chemotherapy is one of the most interesting aspects of this research. However, it is too early to say that RK 251 can replace chemotherapy.
The drug has so far shown promise in preclinical research, particularly against triple negative breast cancer cells. It has not yet been tested in human patients.

Before a new cancer drug can become a treatment option, it must undergo several stages of research and clinical trials to determine whether it is safe, effective and suitable for patients.
The researchers themselves note that more studies are needed before the technology can be tested in patients.

Final Word

Indian researchers have developed RK 251, an experimental smart cancer drug designed to become active mainly inside cancer cells. Early research showed promising activity against triple-negative breast cancer cells, with considerably less effect on healthy cells. However, it is not yet a treatment available to cancer patients. The research is still at the preclinical stage, and further studies are needed before it can be tested in humans.